Using genomic analyses of breast cancers, it was proposed that Trop-2 is a potentially attractive target for triple-negative breast cancer (TNBC) [22], which we reported with RS7 anti-Trop-2 antibody conjugated to a radionuclide [23]. The gene discussed is TACSTD2; the disease is triple-negative breast carcinoma.